Biosimilars, a 1.6 billion euro saving
According to data presented by Iqvia and Egualia, the guaranteed savings from the use of biosimilars would amount to around €1.6 billion. But much remains to be done to ensure access to treatment for all.
The rise of the BRICS
The establishment process of the five most important emerging countries also involves the
pharmaceutical sector. According to research by Iqvia, within three years, four of these nations
will be among the world's leading pharmaceutical markets.
OsMed Report 2020 by AIFA
The strengthening of the Covid Green Pass and the modification of references for adoption of restrictive measures, with the abandonment of the...
